An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
Researchers want to know if irreversible electroporation (IRE), a minimally invasive surgical technique, makes it easier for chemotherapy to reach pancreatic cancer cells.
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Scientists are trying a new type of drug combination that gets activated only in the unique conditions of the tumor microenvironment.
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.